Devyser Diagnostics AB (publ) (STO:DVYSR)

Sweden flag Sweden · Delayed Price · Currency is SEK
108.20
+0.20 (0.19%)
At close: Dec 5, 2025
-12.03%
Market Cap 1.80B
Revenue (ttm) 242.70M
Net Income (ttm) -25.20M
Shares Out 16.65M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE 61.92
Dividend n/a
Ex-Dividend Date n/a
Volume 7,661
Average Volume 17,630
Open 108.20
Previous Close 108.00
Day's Range 106.00 - 108.60
52-Week Range 83.30 - 159.60
Beta 0.75
RSI 39.15
Earnings Date Feb 12, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analys... [Read more]

Sector Healthcare
Founded 2004
Employees 121
Stock Exchange Nasdaq Stockholm
Ticker Symbol DVYSR
Full Company Profile

Financial Performance

In 2024, Devyser Diagnostics AB's revenue was 216.90 million, an increase of 28.12% compared to the previous year's 169.30 million. Losses were -61.50 million, 14.7% more than in 2023.

Financial Statements

News

There is no news available yet.